This article is more than 5 years old. Information may no longer be current.

Novaliq and BLP form Betaliq to develop glaucoma products

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Novaliq and BLP Management Group have formed Betaliq, a company that will develop beta-blockers for the treatment of glaucoma, according to a press release.

Betaliq, based in Tampa, Florida, has two preservative-free glaucoma drug candidates in its pipeline that both use Novaliq’s EyeSol water-free technology.

“With Betaliq, we aim to transform how glaucoma patients can be treated in the future, expanding application of EyeSol to another major indication,” Christian Roesky, Novaliq’s CEO and member of the Betaliq board of directors, said in the release. “Our latest clinical trials in dry eye disease with two topical products based on our unique water-free technology have just demonstrated the difference our products can have for patients with an ocular surface disease. We believe that with Betaliq, we can offer the same impact to glaucoma patients.”

Barry Butler is serving as the CEO of Betaliq, which recently closed a Series A financing round to fund the company and conduct phase 2 trials, the release said.

“I am excited to use this promising water-free technology also for glaucoma,” Butler said in the release. “I believe the advantages offered by the EyeSol platform will bring significant benefits to glaucoma patients.”